An exploratory analysis of actigraphy and sleep diaries in a methamphetamine withdrawal clinical trial

LIAM S ACHESON¹ ² ³, CHRISTOPHER GORDON⁴ ⁵, NADINE EZARD² ³ ⁶, NICHOLAS LINTZERIS⁶ ⁷ ⁸, ADRIAN DUNLOP¹ ⁶ ⁹ ¹⁰, JONATHAN BRETT¹ ¹¹ ¹², CRAIG RODGERS², ANTHONY GILL², MICHAEL CHRISTMASS¹ ³ ¹⁴, REBECCA MCKETIN¹, MICHAEL FARRELL¹, STEVE SHOPTAW¹⁵, KRISTA J SIEFRIED¹ ² ³

¹The National Drug and Alcohol Research Centre (NDARC), the University of New South Wales, Sydney, Australia, ²Alcohol and Drug Service, St. Vincent’s Hospital Sydney, Sydney, Australia, ³The National Centre for Clinical Research on Emerging Drugs (NCCRED), c/o the University of New South Wales, Sydney, Australia, ⁴Susan Wakil School of Nursing and Midwifery, The University of Sydney, Sydney, Australia, ⁵CIRUS Centre for Sleep and Chronobiology, Woolcock Institute of Medical Research, University of Sydney, Sydney, Australia, ⁶New South Wales Drug and Alcohol Clinical Research and Improvement Network (DACRIN), Sydney, Australia, ⁷The Langton Centre, South East Sydney Local Health District, Sydney, Australia, ⁸Discipline of Addiction Medicine, the University of Sydney, Sydney, Australia, ⁹Drug and Alcohol Clinical Services, Hunter New England Local Health District, Newcastle, Australia, ¹⁰School of Medicine and Public Health, the University of Newcastle, Newcastle, Australia, ¹¹Clinical Pharmacology and Toxicology, St Vincent’s Hospital Sydney, Sydney, Australia, ¹²St. Vincent’s Clinical School, the University of New South Wales, Sydney, Australia, ¹³Next Step Drug and Alcohol Services, Perth, Australia, ¹⁴National Drug Research Institute, Curtin University, Perth, Australia, ¹⁵Department of Family Medicine, The University of California Los Angeles, Los Angeles, USA

Introduction and Aims: Sleep disturbance, common during methamphetamine (MA) use and withdrawal, has to date only been assessed by questionnaires in this population. Actigraphy is a well-established, non-invasive measure of the sleep-wake cycle, and has demonstrated comparable accuracy to gold-standard polysomnographic sleep studies. This is the first study to investigate the feasibility and utility of using actigraphy and sleep diaries to investigate sleep during MA withdrawal.

Design and Methods: We conducted an open-label single-arm trial to investigate safety and feasibility of a 5-day tapering-dose regimen of lisdexamfetamine for the treatment of MA withdrawal. Participants were inpatients for 7 days; continuously wore an actigraph (Philips Actiwatch 2), completed a modified Consensus Sleep Diary (CSD) each morning, and were interviewed.

Results: 10 participants (median age 37 years, 90% male) enrolled. Participants interviewed (n=8) reported the actigraph was not difficult or distracting to wear nor was completion of the daily sleep diary onerous. No participant removed the device prematurely. Actigraphic average sleep duration was 646 minutes, sleep onset latency 20 minutes, and wake after sleep onset (WASO) 78 minutes. Sleep diaries under-reported sleep compared with actigraphy (sleep duration 141 minutes (p=0.005) less; WASO 45 minutes (p<0.001) less). Mean sleep efficiency was 83.9% by actigraphy, however participants rated their overall sleep quality at 4.7 on a nine-point scale by CSD.

Discussions and Conclusions: Continuous actigraphy is feasible to measure sleep-wake cycles in people withdrawing from MA, with high accuracy and low participant burden. We found differences in self-reported and actigraphic sleep, requiring further exploration.

Implications for Translational Research: Accurate sleep measurement is essential to better understand stimulant use and withdrawal, and has the potential to be used as an efficacy outcome in future trials and clinical practice in inpatient and outpatient settings.

Presenter’s email: liam.acheson@svha.org.au
Disclosure of Interest Statement:
This research is funded by the National Centre for Clinical Research on Emerging Drugs (NCCRED). NCCRED is funded by the Australian Government Department of Health. No pharmaceutical or medical device manufacturer was involved in any part of this trial.